Catalent, a leader in biotechnology, has been making waves in the news recently, with much attention on their activities in the stock market, and the deal with Novo Holdings. A significant shift for Catalent came following the announcement that they were acquired by Novo Holdings in a $16.5B deal, drawing scrutiny from US Senator Warren. Despite this, Catalent has performed well, with the company beating both Q4 earnings and revenue estimates. The company's stock, NYSE:CTLT, saw an increase, with the shares purchased by Contravisory Investment Management Inc.
In the face of this, some analysts have issued varying opinions regarding the Catalent's stock, with Robert W. Baird reiterating a neutral rating, and the company being upgraded to a strong buy by other market watchers. Despite some selling of shares by major investors, the company's shares remain in a good position. The company continues to invest in itself, as seen with the $25M expansion of its clinical supply facility in Germany.
Catalent CTLT News Analytics from Sat, 15 Nov 2014 08:00:00 GMT to Sat, 12 Oct 2024 06:21:13 GMT - Rating 7 - Innovation 3 - Information 6 - Rumor -3
